Layoff season continues

Share this article:

Layoffs abound.

The fourth-quarter layoff tradition continues. Below, a mini roundup:

Actavis is laying off 30% of its sales staff, having assessed post-Warner Chilcott needs. The deal closed Oct. 1, and Actavis said 350 employees drawn from its sales force, district managers, account managers and management are losing their jobs.

Bayer is releasing 50 employees. Pharmalot found the news in a California filing about the closure of a Sunnyvale, CA, plant associated with its discontinued diabetes monitors A1CNow and A1CNowSelfCheck.

These layoffs come on top of other reorganizations, such as Shire's R&D cuts in Basingstoke, UK; Novartis's pink slipping of California-based researchers; and Merck's layoff of 8,500 workers.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.